<DOC>
	<DOCNO>NCT00384839</DOCNO>
	<brief_summary>The purpose research study find effect ( good bad ) Vidaza patient prostate cancer . This investigational drug approve Food Drug Administration ( FDA ) treatment prostate cancer ; however , approve myelodysplastic syndrome - bone marrow disease . The pharmaceutical company involve study , Pharmion Corporation , manufacturer Vidaza .</brief_summary>
	<brief_title>Vidaza Restore Hormone Thx Prostate</brief_title>
	<detailed_description>This open label Phase II study . Patients receive Vidaza 5 consecutive day ( Days 1- 5 ) 28-day cycle . Complete androgen ablation continue . Response assess minimum 2 cycle ( evaluable patient ) . PSA response evaluate prior cycle % fetal hemoglobin evaluate prior odd cycle ( exclude Cycle 1 ) . Patients treat clinical progression maximum 12 cycle . A total 35 patient advanced metastatic HRPC enrol trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>INCLUSION CRITERIA : A diagnosis histologically confirm , progressive , advanced metastatic , nonmetastatic prostate cancer document PSA progression , calculate PSA double time &lt; 3 month , complete androgen ablation therapy . PSA progression , without clinical progression ( symptomatic/radiologic per RECIST ) require ; measurable disease require . Baseline PSA value must follow 2 serial increase least 2 week apart ( upper limit time 2 sample ) . Calculated PSA double time , PSA value must &lt; 3 month . An automated PSA doubling time calculator may find www.mskcc.org/mskcc/html/10088.cfm ( see study tool ) . Currently complete androgen ablation hormone therapy ( LHRH agonist plus antiandrogen ) testosterone level &lt; 50ng/dL ) . Patients LHRH agonist antiandrogenic therapy entry continue therapy study . Antiandrogen withdrawal necessary preclude enrollment trial . The detail therapy must record CRF . Patients orchiectomy antiandrogen therapy permit study . An elevated PSA level patient progress PSA criterion require ( see protocol specific detail ) . Has Karnofsky Performance Status &gt; 70 Is great 18 year age Must meet specific lab value follow criterion : granulocyte , platelet count , total bilirubin , AST ALT , serum creatinine , calculate creatinine clearance &amp; urinalysis ( see protocol specific detail ) . If fertile , patient agree use acceptable method birth control avoid father child duration study period 2 month thereafter . Has sign Patient Informed Consent Form Has sign Patient Authorization Form EXCLUSION CRITERIA : Has clinical progression without evidence PSA progression Has receive prior chemotherapy Has prior treatment Vidaza Has history hypersensitivity component Vidaza ( mannitol ) Has history New York Heart Association ( NYHA ) heart disease Class III IV ( Appendix III ) myocardial infarction within 6 month prior Day 1 unstable arrhythmia evidence ischemia electrocardiogram ( ECG ) Is receive concurrent immunotherapy Is receive concurrent bisphosphonate therapy ; longstanding bisphosphonate therapy ( initiate &gt; 8 week prior registration ) acceptable . Bisphosphonates start within prior 8 week allow since may affect study endpoint render interpretation difficult . Has receive treatment radiation therapy , surgery , chemotherapy , ketoconazole , corticosteroid , investigational agent within 1 month prior registration , ( 6 week radiation therapy , nitrosureas Mitomycin C ) Has evidence central nervous system ( CNS ) involvement Has serious uncontrolled intercurrent medical psychiatric illness , include serious infection require systemic therapy Has serious uncontrolled nonmalignant disease ( liver failure , condition ) could compromise protocol objective opinion Investigator Has history malignancy within last 5 year ( except cure basal cell carcinoma skin ) , could affect diagnosis assessment study drug Is know positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Is unable comply requirement study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>